



The timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions

Fourth edition

January 2019

Contents

Foreword	3	6. Implementations	20
Executive summary	4	6.1 Availability of resources	20
1. Introduction	6	6.2 Patient-specific reminders at the time of prescription of treatment	20
2. Background	8	6.3 Communication	20
2.1 Introduction	8	6.4 Audit	20
2.2 How often do interruptions arise in radiotherapy centres and why?	8	6.5 Audit of key outcome indicators	21
2.3 Therapies and tumour types	8	6.6 Quality assurance	21
2.4 Does the length of the interruption matter?	9	6.7 Funding	21
2.5 Does the timing of the interruption matter?	10	6.8 Supervision	21
2.6 The need for departmental protocols	11	6.9 Teaching	21
2.7 Interruption policies	11	6.10 Radiobiology support	21
2.8 Conclusion	11	7. Governance	22
3. Prioritisation of patients on treatment	12	7.1 Responsibilities associated with the introduction of biologically corrected doses	22
3.1 Category 1	12	7.2 Changes in treatment	22
3.2 Category 2	13	Appendix A. The coding for evidence-based recommendations	23
3.3 Category 3	13	Appendix B. Worked examples of biological compensation	24
3.4 Summary	13	References	32
4. Management of potential prolongation of a treatment schedule	14	Working party membership	38
4.1 Preventative measures – how can interruptions be avoided?	14		
5. Compensatory measures	17		
5.1 Transfer to a second machine	17		
5.2 Accelerated scheduling	17		
5.3 Biological allowance	17		

This document has been endorsed by:



This document has been supported by Royal Australia and New Zealand College of Radiologists.

Foreword

Radiotherapy is an important part of the curative treatment of many cancers. Cancer cells can grow and repopulate between treatments therefore the overall treatment time should be kept as short as possible. Gaps in radiotherapy can enable this repopulation of cancer cells to accelerate, leading to potentially lower cure rates.

Good clinical practice dictates that radical courses of radiotherapy treatment should not be interrupted; however, where interruptions are unavoidable, compensatory treatment is required.

In 1996 the College produced the first guidelines for the management of unscheduled interruptions in a course of radical radiotherapy and later published second (2001) and third editions (2008).¹⁻³ The 2008 edition was highly influential in ensuring that oncology departments set up local protocols to minimise the impact of unscheduled interruptions; indeed, ten years on, most of the recommendations in the guidance now form the standard of care for patients receiving radical radiotherapy.

The fourth edition of the guidance has been updated to take account of a number of developments in clinical practice in recent years. This edition has updated the 'category' sections and in particular includes new information relating to breast, anal and lung cancer. The guidance has also been updated to take account of the adoption of new radiotherapy techniques including sections on stereotactic ablative radiotherapy (SABR) and proton beam therapy (PBT) treatment gaps.

We are not aware of any other guidance document that comprehensively addresses radiation therapy treatment gaps.

I would like to thank Professor Geoff Higgins and Dr Ketan Shah as co-chairs of the working party, as well as Ms Paula Horne, Mr Mark Gilham, Dr Kevin Franks and Professor Roger Dale for their contribution to the review.

I would also like to extend my thanks to Dr Duncan Gilbert, Dr Anna Kirby, Dr Ian Geh, Dr Melanie Powell, Professor David Dearnaley and Dr Dan Saunders for their help with the literature review, as well as to Dr James Coates and Ms Sarah Griffin for their project support. I am very grateful for all those who helped by reviewing and commenting on this fourth edition in particular the Institute of Physics and Engineering in Medicine (IPEM) and the Royal Australian and New Zealand College of Radiologists (RANZCR) for their expert advice.

Dr David Bloomfield
Medical Director, Professional Practice, Clinical Oncology

Executive summary

Good clinical practice dictates that radical courses of radiotherapy treatment should not be interrupted. Where interruptions are unavoidable, compensatory treatment is required.

For a wide range of fast-growing tumours, there is evidence that uncompensated interruptions to radiotherapy, resulting in prolongation of overall treatment time, increase the risk of local recurrence of these tumours.⁴ This applies not only to those receiving radical primary radiotherapy but also to those being treated with radical postoperative radiotherapy,⁵ chemoradiotherapy and those being treated with combined brachytherapy and external beam therapy,⁶⁻⁹ where overall treatment time is the time for the combined therapy. Mathematical modelling of the data from various studies suggests that an unscheduled gap of one day can result in an absolute reduction of local control by 1.4%.¹⁰ A separate clinical study reported that a prolongation of overall treatment time by two days when treating patients with laryngeal tumours over four weeks significantly affected treatment outcome.¹¹

The effect of treatment prolongation has not been investigated in all fast-growing tumours and there have only been a few studies into the effect of interruptions on the outcome of treatment for patients with slow-growing tumours. However, in keeping with good clinical practice, it is to be expected that any interruption to radiotherapy schedules may affect outcome.

Although the volume of published evidence for the effects of treatment prolongation on outcome is small, it must be appreciated that the rules of evidence-based medicine¹² were intended for use in evaluating the benefits of therapeutic interventions. They were not proposed for evaluating the risks of exposure to potentially avoidable hazards. Although we have categorised patients into three groups, there is no theoretical reason to state that there is any threshold below which an interruption is safe. We recommend that steps be taken to prevent any interruptions in therapy. In situations where they arise, we recommend the adoption of Mackillop's ASARA principle that interruptions should be 'as short as reasonably achievable'.¹³

Patient categorisation

Three groups are proposed when prioritising patients according to the need to manage interruptions. The distinction between the three categories is determined by tumour type and treatment intent.

Category one patients

These are patients with rapidly growing tumours, such as squamous carcinomas of the head and neck and anus, being treated with radical intent. The effects of interruptions on the outcomes of such cancers have been assessed by a number of international studies.^{14,15} Treatment duration must not be prolonged by more than two days over the original prescription.

Category two patients

These are patients with slower growing tumours, usually adenocarcinomas, being treated with radical intent. There are reports that prolongation of five days may not always be deleterious,^{16,17} but no safe minimum has been established. It is advised that their treatment should not be prolonged by more than two days over the original prescription.

Category three patients

These are patients being treated with palliative intent. Overall time is less critical in achieving the desired palliative outcomes. Prolonged interruptions, which may occur because of intercurrent illness, may require compensation, particularly if longer than seven days.

Service provision

This document describes in detail the steps which departments should take to deliver a satisfactory service for their patients and defines good standards of care.

Departments must establish robust systems of service planning, according to local protocols, to cope with predictable and unpredictable interruptions to normal treatment.

Planning the overall service

- Working across bank holidays or scheduling additional treatments to avoid prolongation of a patient's treatment should remain the norm.
- The impact of machine servicing and quality assurance on the continuity of patients' treatment must be carefully considered in scheduling these activities.
- The provision of adequate resources in terms of machines, staff and training must be the subject of long-term planning.
- Patient transport must be organised to ensure continuity of treatment.

Management of unavoidable or unscheduled interruptions

Such episodes may arise as a result of machine breakdown, staff or patient illness. The following measures are recommended for the management of any potential interruption in treatment or prolongation of time schedules.

- The ideal procedure is to transfer all patients to a matched linear accelerator on the day of interruption.
Where this is not possible the following approaches are recommended.
 - Where possible, there should be the facility that allows patients who have missed scheduled weekday treatments to be treated at the weekend. Departmental protocols must ensure that complex treatments can be safely delivered out of normal hours.
 - Patients can be treated twice daily, with a minimum of six hours between therapies.¹⁸
 - Use of biologically equivalent dose (BED) calculations to derive an alternative schedule involving a modified number of treatment fractions with which to complete the radiotherapy course in the planned overall time, but perhaps accepting a higher BED in normal tissues.¹⁹
 - The addition of extra treatment fractions where compensation cannot be achieved within the original overall planned time.
- Each radical prescription should be prospectively reviewed to ensure that the prescriber's intention will be delivered.

1. Introduction

Radiotherapy is an important modality in the management of patients with cancer. About four in ten people with cancer (40%) have radiotherapy as part of their treatment.²⁰ The key concept that to achieve cure of a patient with cancer, radiotherapy must eradicate every tumour stem cell, has been recognised for over 50 years.²¹

All the stem cells associated with the tumour plus any additional stem cells generated during the course of treatment by continuing cell division must be included in the target volume.²² The probability of eradicating a cancer with a given dose of radiation is inversely related to the number of stem cells present in the treatment volume.²³

The rate of cell division varies widely among similar tumours and different tumour types.^{24–26} The longer a course of treatment, the more stem cells can repopulate, increasing the number of stem cells that have to be obliterated. As overall treatment time increases, the probability of local control/cure by radiotherapy decreases. Those cancers which show rapid cellular repopulation will be less likely to be cured when the overall treatment time is extended.²⁷

This document represents the response of the RCR to concern about the potential adverse effects of unscheduled treatment interruptions on outcomes for patients receiving a radical course of radiotherapy.

The types of evidence and the grading of recommendations used within this document are those previously defined by the Scottish Intercollegiate Guidelines Network (SIGN)²⁸ as specified in Appendix A. Undertaking randomised clinical trials to ascertain the degree of harm caused by treatment delays is clearly neither helpful nor ethical. However, there is strong evidence from multiple clinical series that interruptions increase the risk of local failure, based on worse outcomes for patients whose radiotherapy is interrupted. The evidence that interruptions cause an increase in the risk of local recurrence is unassailable.^{10,14,15,29–31}

A 2007 review of the quality of evidence and the strength of recommendations³² drew attention to the four key determinants of the strength of a recommendation: first, the balance between desirable and undesirable consequences of alternative management strategies; second, the quality of the evidence; third, the relative uncertainty about patient preferences; and finally, cost. Evidence continues to accumulate highlighting the fact that uncompensated interruptions in radiotherapy disadvantage the patient and increase the risk of local recurrence and death from cancer. In this document the quality of evidence for statements is explicitly presented. It is clear that there is no reason for most patients to want an interruption to their recommended radiotherapy as it risks compromising the chance of cure. There will be a cost in providing adequate provision to compensate for interruptions but the savings in sparing recurrence will offset this. Overall, radiotherapy has been shown to be a remarkably cost-effective service.^{33–36}

This document outlines best practice for the continuity of a course of radical radiotherapy. It specifies evidence-based categorisation of patients according to their tumour type. The evidence relating to the effect of prolongation of overall treatment time on therapy outcome for patients with tumours arising at various sites is based on cohort studies,^{14,15,29,37,38} mainly on fast-growing squamous tumours of the head and neck.

The effect of treatment prolongation has not been investigated on all fast-growing tumours. Some cancers are too rare to permit an accumulation of such evidence and for those we have to rely on expert opinion; this forms a small minority of our recommendations.

There have only been a few studies into the effect of interruptions on the outcome of treatment for patients with slower growing tumours. However, in keeping with good clinical practice, interruptions to radiotherapy schedules in the management of this group should also be minimised, as it is to be expected that they will affect outcome.

The patients are categorised into three groups, but there is no theoretical reason to state that there is any threshold below which an interruption for those placed in Category two is safe. We recommend that steps be taken to prevent and minimise any interruptions in therapy. In situations where they arise we recommend the adoption of Mackillop's ASARA principle that interruptions should be 'as short as reasonably achievable'.¹³

This document discusses ways of overcoming interruptions to treatment. Some of these are based on radiobiological models which have been developed over the past 40 years. Consideration has been given to the position of the 'gap' a) in relation to the day of the week and b) in relation to the time of the start of therapy. In these situations, it has been necessary to extrapolate data from animal and laboratory studies to draw some conclusions.³⁹

The implementation of these national guidelines will be best achieved if they are incorporated locally into departmental protocols. This document is designed to assist clinical oncology departments to achieve this by identifying:

- Which categories of patients are most at risk of loss of tumour control/cure rates from unscheduled interruptions
- The causes of unscheduled treatment interruptions
- How such interruptions in treatment may be prevented
- How to manage unavoidable interruptions to minimise the impact on treatment outcome.

The guidelines highlight the role of the consultant clinical oncologist in the decision process. The identification of patients whose radiotherapy treatments have been interrupted and the estimation of what changes in treatment are necessary to compensate for the anticipated prolongation are usually carried out by radiographers and physics staff respectively. The final decision regarding what changes in therapy are implemented depends on the consultant clinical oncologist. S/he will interact with radiographers, physics staff and clinical nurse specialists and make a decision after considering what effect the proposed changes will have on the patient in question both in the short and long term.

This publication updates the third edition³ which is now withdrawn.

2. Background

2.1 Introduction

'Conventional' radical fractionation schedules evolved to accommodate the standard working practice of weekend breaks and are considered to compensate empirically for tumour repopulation during the non-treatment days. The addition of further interruptions to the planned schedule, which potentially result in prolongation of overall treatment time, will affect outcome.

2.2 How often do interruptions arise in radiotherapy centres and why?

Reports^{11,31,38,40-44} in the 1980s and 1990s revealed that more than 30% of radical treatments to patients with squamous cell carcinomas (SCC) of the head and neck region were interrupted. The most common causes were public holidays, machine service time, equipment breakdown and patient related issues.^{37,45,46} The audit of head and neck cancer in 2005 from the RCR⁴⁶ showed that 63% of patients had one or more treatment interruptions. However, with the introduction of local protocols from the guidelines,^{1,2} compensation was applied and 88% of interrupted cases completed treatment within one day of target, suggesting a growing awareness of the importance of avoiding treatment interruptions.

2.3 Therapies and tumour types

There is an increasing body of evidence^{4,10,14,15,29,30} that unplanned interruptions of radical radiotherapy treatment resulting in prolongation of overall treatment time detrimentally affect local control and cure rates for patients with certain tumours. Recent data suggest that this applies to those receiving:

- Radical primary radiotherapy
- Radical postoperative radiotherapy^{5,47}
- Combined brachytherapy and external beam therapy^{6-8,48,49} (the overall treatment time is the time for the combined therapy)
- Chemo/radiotherapy combinations^{49,50} (the overall treatment time is the time for the combined therapy).

The tumour types reported in the literature as being most affected by interruptions include:

- Head and neck squamous cell carcinomas (HNSCC)^{15,51,52}
- Cancers of the cervix^{48,53-57}
- Cancers of the lung: a) non-small cell (NSCLC)^{50,58-61} and b) small cell (SCLC)^{49,62-64}
- Cancers of the oesophagus⁶⁵⁻⁶⁸
- Medulloblastoma and primitive neuroectodermal tumours (PNET)⁶⁹⁻⁷¹
- Anal squamous cell carcinomas.⁷²⁻⁷⁴

The mechanism is likely to be repopulation of tumour clonogens due to either a de novo high proliferating fraction or accelerated repopulation occurring in response to anti-neoplastic treatment.

It is usually assumed that the outcome for patients with any fast-growing tumour will be adversely affected by treatment interruptions, even in cases where there is no direct evidence. Glioblastomas are very fast-growing tumours, and there is evidence that delay in starting therapy affects outcome.^{75,76} However, there are no reports on the effect of

breaks in treatment on outcome; additionally, the complexities of repair in the brain make recommendations for compensation strategies more complex.

There is more uncertainty regarding transitional carcinoma of the bladder.⁷⁷⁻⁸⁰ Two small reports^{78,79} suggested that prolonging treatment of patients with bladder cancer might affect outcome, but two larger retrospective studies from Holland and Belgium showed no significant effect of prolonging treatment time on outcome.^{77,80}

The biological behaviour of slower growing tumour types is such that it has been reported that a prolongation of five days does not significantly affect patient outcome – local control and survival – as determined by statistical analysis. This would appear to apply to patients with carcinomas of the anus⁸¹⁻⁸³ receiving chemoradiotherapy. The data for adenocarcinoma of the prostate is inconclusive.⁸⁴⁻⁸⁷

For breast cancer, two series have been reported showing an adverse effect on both local control and survival if treatment was prolonged for more than seven days (grade D recommendation, see Appendix A) in a five-week course of treatment.^{16,17} There are no published data on shorter courses of treatment. We recommend that treatment should fall within Category 2 – that is that treatment should ideally not be prolonged by more than two days (grade D recommendation).

Palliative treatment schedules are administered to alleviate symptoms such as pain or bleeding, or to obtain local tumour control to prevent ulceration. They may also aid healing of ulcers and reduce tumour mass causing pressure symptoms.

Prolongation of these schedules may reduce the effect achieved and/or duration of benefit, for example, the management of cord compression and superior vena cava obstruction (SVCO). The mechanisms for unscheduled treatment extension compensation are the same as for radical therapy. In this situation, there is greater scope for hypofractionation, provided that tissue tolerances are respected. The clinical situation will determine whether a correction is needed but would usually be recommended if the prolongation exceeded seven days.⁸⁸

2.4 Does the length of the interruption matter?

The minimum length of an interruption which results in prolongation of treatment time that will have a significant effect on local tumour control is difficult to determine, especially when standard departmental treatment times may vary by two days depending upon which day of the week treatment is commenced. Data from split-course therapy studies³⁸ show that 14–16 day interruptions definitely affect treatment outcome. A relative loss of local control ranging from 3–25% (median 14%) arises when a treatment prolongation of one week^{30,89} occurs. Mathematical modelling of data from patients with SCC of head and neck, cervix and lung suggests that an unscheduled interruption of one day can, if left uncompensated, result in an absolute reduction of local control of some tumours by 1.0–1.4%.^{4,9,10}

A report considering the effect of lengthening combined brachytherapy and external beam therapy in the management of patients with SCC of the tonsil suggested that lengthening the overall treatment time for the combined therapy beyond 42 days significantly reduced local control rates.⁶

For SCC of the anus, data from the large randomised trials have been retrospectively analysed with respect to radiation treatment time, and its correlation to local failure and overall survival. For the Radiation Therapy and Oncology Group (RTOG) trials 87-04 and

98-01, an effect for total (multimodality) treatment time was observed.⁷² Ongoing analysis of the ACT2 trial data also supports a deleterious effect from increasing overall radiotherapy treatment time.⁷⁴

For locally advanced NSCLC there is evidence that radiotherapy delays have a negative effect on overall survival for patients receiving concurrent chemo-radiotherapy. A large retrospective study found there was a significant difference in overall survival (OS) for those patients without delays compared to those with delays (median OS 22.7 versus 18.6 months $P < 0.0001$). In addition, with each cumulative delay, overall survival worsened (standard radiotherapy versus prolonged 1–2 days, 20.5 months, $P < 0.009$; prolonged 3–5 days, 17.9 months, $P < 0.0001$; prolonged 6–9 days, 17.7 months, $P < 0.0001$; prolonged >9 days, 17.1 months, $P < 0.0001$).⁶¹

In limited stage SCLC treated with concurrent chemotherapy, 45 Gray (Gy) in 30 fractions given twice a day over three weeks, was superior to 45 Gy in 25 fractions given over five weeks for overall survival with a four-month improvement in median overall survival ($p = 0.04$).⁶³ The recently published CONVERT trial comparing 45 Gy in 30 fractions given twice a day versus 66 Gy in 33 fractions showed a non-significant trend ($p = 0.14$) for improved overall survival in the hyperfractionated arm.⁶⁴ In addition, in the CONVERT trial there were strict rules regarding any unplanned treatment gaps to avoid treatment prolongation. These combined results suggest that a short overall treatment time is important in SCLC and treatment delays should be compensated for.

For locally advanced cervical cancer, there is evidence that overall treatment time should be as short as possible and should not exceed 56 days for squamous carcinoma.^{7,8,48,55–57,90}

Adenocarcinoma may respond differently. There are only two reports on breast cancer.^{16,17} These show that prolongation of more than seven days for those with carcinoma of the breast receiving postoperative irradiation over five weeks results in an increased risk of local recurrence and death.^{16,17} Analysis of data from the START A and B trials⁹¹ hypothesises that the shorter overall treatment time in the hypofractionated regimes for adjuvant whole-breast radiotherapy is a significant contributor in maintaining local cancer control. Overall treatment time should therefore be delivered as planned.

2.5 Does the timing of the interruption matter?

There is some controversy over whether the timing of the interruption in the treatment schedule is important. The position of an unscheduled interruption does not yet appear to be significant.^{29,31,92,93} This may change as more studies are carried out on the data available from meta-analyses.^{94–97} Accelerated repopulation, which is apparent in some tumour types after 28 days of radiation treatment, alters the K-factor (a factor used to determine the amount of radiation 'wasted' due to ongoing tumour repopulation). Future studies might show that gaps arising in short courses of treatment and those arising earlier than 28 days in a long course of therapy have a different effect from those arising later in a long course. Biological corrections for these events will be different. Correction for interruptions arising later in a long course of therapy is more difficult since it may require the patient to receive a number of large fractions over a short period of time and this may risk increasing long-term late effects.

It has been suggested from animal data using normal pig skin that the day of the week on which an interruption occurs may affect response to radiotherapy.³⁹ Extrapolating this observation to tumour control would suggest that an interruption on a Monday or Friday

which lengthens the weekend break by 33%, may have a more serious adverse effect than an interruption mid-week.⁹⁸ Further studies are required to investigate whether such details of the timing of an interruption are important in determining its effect on tumour control in man.

2.6 The need for departmental protocols

The development and implementation of guidelines for the identification of patients potentially at risk and how to prevent or manage unplanned prolongation of therapy are a health priority. Implementation of such guidelines in local healthcare plans and audit plans has the potential to improve the local tumour control rates in certain tumour types, reducing long-term healthcare costs.

In 2000, the RCR Clinical Oncology Audit Sub-Committee undertook a national audit of the management of interruptions arising in the radical treatment of patients with squamous cell carcinoma of the head and neck attending the 55 cancer centres in the UK.⁴⁵ This was repeated in 2005.⁴⁶ The audits were based on the first and second editions of the *Guidelines for the management of the unscheduled interruption or prolongation of a radical course of radiotherapy*.^{1,2}

The outcome measures of the audit were:

- Frequency and causes of interruptions to therapy
- Policy and compliance with policy for managing interruptions
- Prolongation
- Time between first visit to clinic and start of treatment.

2.7 Interruption policies

In 2000, seven centres (13%) were unable to introduce any policy due to local circumstances. The remainder adopted one or more of the policies recommended by the RCR.² This was confirmed by a subsequent survey by Dale *et al.*⁹⁹

The RCR re-audit in 2005 showed that the guidelines and the local adoption of policies had improved the delivery of radical radiotherapy schedules. Sixty-three per cent of the 631 patients registered in 2005 by 48 of the 57 centres had one or more treatment interruptions compared to 60% of the 2,553 cases registered in the 2000 audit.⁴⁷ However, in 2005, 88% of patients with interruptions completed treatment within one day of target and 95% within two days compared to 69% within two days in 2000.

In 2000, the 48 centres that had incorporated bank holiday working into their policies were able to comply with their policy more often (74% versus 49% of cases) and more frequently apply a remedy (86% versus 69% of cases) than those centres that did not treat patients on a bank holiday.

2.8 Conclusion

The available data strongly suggest that unscheduled and uncompensated prolongation of radical treatment adversely affects local tumour control in a number of tumour types. For this reason, it is extremely important that each department has its own protocols to compensate for unscheduled interruptions. The longer a gap is, the more damaging is the effect.

Many interruptions are predictable and can be planned for.

3. Prioritisation of patients on treatment

Tumours grow at different rates. Even within any one tumour type there will be a wide range of tumour growth rates. Tumour volume doubling time is the most practical way to assess growth rate. The volume doubling time is determined by cell cycle time, growth factor and rate of cell loss. The potential cell doubling time (T_{pot}) is another means of assessing growth rate and is defined as the time which the cell population of tumour doubles if there is no cell loss. This is difficult to determine *in vivo*. Patients on treatment should be prioritised within the three categories defined below. Those with tumours in Category 1 tend to have tumours such as squamous cell carcinomas with a relatively short volume doubling time. Those in Category 2 will have tumours such as adenocarcinomas that have a longer volume doubling time.

3.1 Category 1

Patients with the tumour types for which there is evidence that prolongation of treatment affects outcome, and who are being treated radically with curative intent. The data reviewed⁴ show very strong evidence that prolongation of overall treatment time affects treatment outcome or local tumour control (cure rates) in patients with the tumours listed below.

Any audit of this category of patient – departmental or national – should show that there was no prolongation of overall treatment time in excess of two days for at least 95% of the group.

3.1.1 External beam radiotherapy

Patients with the following tumours should not have their radical radiotherapy prolonged:

- Squamous cell carcinoma of the head and neck region^{29,31,45,51,92} (grade B recommendation based on level 2⁺⁺ evidence)
- Non-small cell lung carcinoma (NSCLC)^{50,58,59,100} (grade C recommendation)
- Squamous cell carcinoma of the cervix^{7,48,53–57,84} (grade D recommendation)
- Small cell lung carcinoma^{49,62} (chemoradiotherapy) (grade D recommendation)
- Squamous cell carcinoma of oesophagus^{65–68} (grade D recommendation)
- Squamous cell carcinoma of skin, vagina or vulva (grade D recommendation)
- Squamous cell carcinoma of the anus⁷² (grade C recommendation)
- Adenocarcinoma of the oesophagus⁶⁶ (grade D recommendation)
- Medulloblastoma and primitive neuroectodermal tumours (PNET)^{69–71} (grade B recommendation based on level 2⁺⁺ evidence)
- Patients with tumours with a short mass-doubling time²⁷ (grade D recommendation based on level 4 evidence).

3.1.2 Combined external beam radiotherapy and brachytherapy

Patients with the following receiving brachytherapy plus external beam therapy should not have the combined overall treatment time prolonged:

- Squamous cell carcinoma of the cervix^{8,48,57} (grade B recommendation)
- Squamous cell carcinoma of the tongue⁶ (grade C recommendation)
- Squamous cell carcinoma of the anus^{72,73} (grade D recommendation).

3.2 Category 2

Patients with slower growing tumour types, who are being treated radically, where interruptions in radiotherapy leading to an extension of overall treatment time of more than five days are detrimental to both local control and survival.^{16,17} No safe lower limit has been established and we recommend that where possible treatment should not be prolonged for more than two days.

Any audit of this category of patient – departmental or national – should show that there was no prolongation of overall treatment time in excess of two days for at least 95% of the group. It is accepted however that a prolongation of five days may not affect outcome in this category of patient.

- There is no evidence about prolongation of standard (three-week) courses of radiotherapy for breast cancer. We recommend that treatment should fall within Category 2 – that is, that treatment should not ideally be prolonged by more than two days (grade D recommendation).
- Patients with adenocarcinoma of the breast^{16,17} receiving postoperative therapy over five weeks or more should not have their radical treatment prolonged by more than five days (grade C recommendation).
- Patients with transitional cell carcinoma of the bladder⁷⁷⁻⁸⁰ (grade D recommendation).
- Patients with carcinoma of the prostate⁸⁴⁻⁸⁷ (grade D recommendation).

Some form of compensation should be introduced where the interruption results in a prolongation of overall treatment time of more than five days.

3.3 Category 3

Patients being treated palliatively.⁸⁸ Overall time is less critical in achieving the desired palliative outcomes. Prolongation, which may occur because of intercurrent illness, may require compensation, particularly if longer than seven days.

3.4 Summary

Ideally, there should be no breaks in the delivery of any radiotherapy treatments especially those given with radical intent. If there are adequate facilities in a department there should be no need, except in certain medical situations, for any patient to experience an uncompensated break in treatment.

It is strongly recommended that all patients receiving radical radiotherapy should have the delivery of their treatment schedule audited. Ideally, this should be correlated with outcome to determine if there are other tumour types affected by unscheduled prolongation of treatment time, which should be incorporated into Category 1.

4. Management of potential prolongation of a treatment schedule

4.1 Preventive measures – how can interruptions be avoided?

The five major causes of unscheduled interruptions in a course of radical radiotherapy are:

- Machine and staff availability
- Public holidays
- Transport problems
- Medical problems
- Social circumstances that lead to a patient's failure to attend for treatment as scheduled.

4.1.1 Machine and staff availability

Centres treating patients radically should have ready access to a minimum of two fully staffed and operational linear accelerators at all times, either within the centre or at a second centre situated close by, with clear arrangements for transfer. It is vital that centres can provide continuity of care.

The issues to be dealt with are availability of resources, machine servicing and quality assurance (QA), and how to deal with unplanned downtime.

Machine servicing schedules and QA procedures account for ten to 15 working days annually. Each department must make arrangements to ensure that any interruption to patient treatment is minimised by these processes. If patient transfer to a matched machine (see below) is not possible then this work should be carried out during weekends or out of hours. This can be difficult as it puts an added strain on staff groups already working under pressure and suppliers are not always available to provide necessary support at these times.

Ideally, each centre should have sufficient resources compatible with the departmental workload to allow a percentage of patients to be transferred to an alternative, matched machine should an interruption occur (grade D recommendation based on level 4 evidence).

Where departments have adopted advanced radiotherapy techniques, there should be multiple designated, matched machines available to allow the patient's treatment to continue uninterrupted (grade D recommendation based on level 4 evidence). For those departments with only one machine capable of treating patients with a particular advanced technique, in case of breakdown, it is recommended to convert treatment to a conventional plan rather than to leave a prolonged gap in treatment.

Machine breakdowns can cause severe disruption even though the uptime of modern accelerators is typically very high. Uptime can be maximised by good engineering support either in house or through manufacturers' engineers working under service contracts. There should be robust arrangements for the quick supply of parts for linear accelerators. Centres should have a contingency plan to deal with service interruptions and the system should be flexible to permit transfer of patients rather than send them home.

For prolonged interruptions lasting longer than a few days, it might be necessary to agree a contingency plan with another provider to make up any major shortfall. This would be a complex undertaking. The new provider would have to allocate a consultant to act as a practitioner who prescribes the remainder of the treatment. Replanning of patients' treatment will be required unless the linear accelerators involved are compatible. There

would also be major issues of staffing. Staff transfer might be difficult, they may not be trained to use the machines at the second site. Transport would have to be arranged.

Where patients are being treated by combined external beam and brachytherapy, corrections should be considered for the smallest of interruptions. There should be at least one brachytherapy theatre list per week with the option of a replacement if there is a loss of a scheduled list. Treatments within the department should be organised so that brachytherapy and external beam therapy can be integrated smoothly so that the overall treatment time is kept to the minimum with a maximum prolongation of 1–2 days (grade D recommendation based on level 4 evidence).

Centres must have adequate numbers (at least in line with national recommendations) of radiographers, physicists, dosimetrists and engineering staff.

Departments should ideally aim to minimise the number of weekend breaks in a treatment course, for example by starting treatment on a Monday (grade D recommendation based on level 4 evidence).

4.1.2 Public holidays

There are at least seven bank holidays each year in the UK. It is recognised that interruptions caused by public holidays affect treatment outcome. Ideally all patients should still be treated on public holidays (grade D recommendation based on level 4 evidence). If this cannot be arranged then the treatment of patients in Category 1 should be prioritised. The advantages of a department having a recognised policy for the management of unscheduled interruptions has been described.⁴⁵ Treating on public holidays will have many consequences, including staffing, transport and other hospital support services.

Patients in Category 2 may also benefit from being treated similarly when two or more consecutive treatment days will otherwise be lost.

4.1.3 Transport problems

Every oncology centre must have an efficient means of communication with its local ambulance service and volunteer car service. If it intends to provide twice-daily treatments or weekend treatments as a way to compensate for interruptions, then special arrangements with one or both of these services will have to be established. To facilitate the organisation of treatments, each department should have an efficient booking system which links treatment machines, transport and servicing arrangements (grade D recommendation based on level 4 evidence).

4.1.4 Medical problems

Interruption of treatment is sometimes caused by intercurrent disease or as a consequence of acute radiation reactions.¹⁰¹ Every effort must be made to ensure that these reactions are managed to reduce the risk of treatment delay. This requires proactive support from appropriate healthcare professionals to ensure that the reactions are minimised. Written guidance to patients at the start of treatment facilitates the recognition and management of early reactions (grade A recommendation based on level 1+ evidence). Clinical nurse specialists and review radiographers play an important role in the management of these cases and 'drop-in' clinics are beneficial to all patients receiving radiotherapy as they allow patients to have their symptoms treated early, before they become troublesome and lead to interruption of their radiotherapy.

4.1.5 Psychosocial circumstances leading to a failure to attend for treatment

Patients must be made aware of the importance of daily attendance for treatment and this should be clearly stated before treatment starts, ideally in writing. Psychological and social work support should be given where required to patients and their families.¹⁰² This will help reduce the risk of patients failing to attend (grade D recommendation based on level 4 evidence).

5. Compensatory measures

There are a number of procedures that can be adopted to prevent or minimise the effects of prolongation of overall treatment time. One or more should be adopted by each cancer centre and formalised in a departmental protocol.

5.1 Transfer to a second machine

Ideally patients in Category 1 and, where possible, those in Category 2, should be treated daily (allowing for normal weekend breaks). If the potential interruption is due to machine unavailability – breakdown or service – patients should be transferred to an alternative, matched machine. This can be done with the minimum of effort within any department if the unit has matched linear accelerators.

Departments are encouraged to consider this need when planning new or replacement equipment. Each department should develop its own protocol to allow patient transfer without delay. One means of facilitating this is to prepare contingency plans for an alternative, matched machine at the time of initial planning for radical treatment courses. A service continuity machine allows patients and staff to be moved as required when one linac is down for service or repair.¹⁰³

In any department where patients are being treated with advanced radiotherapy techniques, two matched linear accelerators should be identified as the treatment machines so that patients can be readily transferred, should the machine they are being treated on be unavailable for therapy. For those departments with only one machine capable of treating patients with advanced radiotherapy techniques, in case of breakdown, it is recommended to convert treatment to a conventional plan rather than leave a prolonged gap in treatment.

5.2 Accelerated scheduling

When treatment has been interrupted unexpectedly by only a few days, the scheduled treatment time might be maintained by treating the patient over the weekend. Departmental policies should ensure the safety and quality of weekend treatment. Attempts to treat routine patients using protocols developed for emergency weekend cover would be unsafe.

An alternative is to treat twice daily on some of the other days remaining between the interruption and the end of treatment. Transport restrictions and the lack of day facilities may make this difficult. Where such an approach is possible, the time between the treatments should be a minimum of six hours.^{18,104} Twice-daily treatment is not recommended when fraction size is significantly greater than 2.2 Gy.

5.3 Biological allowance

If an interruption occurs late in the course of radiotherapy for whatever reason, it may be impossible to compensate for the gap in treatment by an accelerated method as described in Section 5.2, in which case it will be necessary to increase the total dose and/or dose per fraction. This will require the use of radiobiological-based calculations. It should be stressed that these should only be adopted when other methods of compensation cannot be applied. In these cases, assumptions need to be made for parameter values, particularly in tumours which have greater variation than late responding tissues. There are circumstances where this will require a model-based estimate of the correction, as discussed by Dale *et al.*¹⁹

5.4 Increased total dose

Various analyses have been used to determine by how much the total dose should be increased to compensate for lengthening of the treatment time. Early estimates^{10,94,105–112} indicated that head and neck K factors (dose/day, Gy·day⁻¹) were in the range 0.5–0.74 Gy·day⁻¹. A K factor is the factor used in standard biologically effective dose (BED; a measure of biological dose delivered to a tumour or organ) calculations to determine the amount of radiation ‘wasted’ due to ongoing tumour repopulation. This is equivalent to the λ/α factor used in some publications.

A meta-analysis of data from Edinburgh, Glasgow, Manchester and Toronto¹⁵ estimates the K value to be 0.89 (95% confidence limits, 0.35–1.43) Gy·day⁻¹. This is supported by the results of the RTOG 9003 head and neck trial⁹⁵ and the analyses carried out by Withers⁹⁶ and Fowler and Harari⁹⁷ who suggest K values of 0.94–0.99 Gy·day⁻¹. It is important to realise that the selected K value must be viewed in conjunction with the time after the start of treatment at which fast tumour repopulation is assumed to begin. For head and neck cancers, Dale *et al*¹⁹ suggest a working value for K of 0.9 Gy·day⁻¹, in conjunction with a delay time of 28 days.

5.5 Compensating for other types of radiotherapy: stereotactic ablative radiotherapy (SABR), proton beam therapy (PBT) and superficial radiotherapy

SABR

The use of stereotactic ablative body radiotherapy (SABR) to deliver a high radiation dose using a small number of treatment fractions has become firmly established in the UK. It is likely to become even more commonly used in the future if the potential indications expand to include routine treatment of oligometastatic disease or of central thoracic tumours. There are currently insufficient clinical data to reliably estimate the effects that SABR treatment delays might have on tumour control. It has been hypothesised that giving SABR on non-consecutive days allows for tumour reoxygenation and may actually improve the efficacy of treatment. A retrospective analysis of SABR outcomes found a non-significant trend towards improved OS in patients treated with non-consecutive rather than consecutive treatments.¹¹³ In addition, a small pilot randomised controlled trial (RCT) suggested that the use of daily lung SABR fractions increased the frequency of \geq grade 2 toxicities.¹¹⁴ Accelerated scheduling is therefore not appropriate for patients receiving SABR, and treatment on non-consecutive days should resume after any unintended treatment delays.

Proton beam therapy

Limited data exist to guide the management of treatment interruptions during proton beam therapy. In general, the principles are the same as for photon treatments.¹¹⁵ As proton services are developed, plans to minimise unplanned treatment interruptions should be incorporated.

Superficial X-ray

Some Category 1 SCC patients may be treated using kilovoltage treatment units, for which there is usually only one in a department. These treatments are often high dose per fraction (\geq 5Gy), so are not suitable for twice daily treatment compensation. However, they are also usually treated less than daily (for example two to three times a week) so any missed

treatments can typically be made up on remaining days. Intra-operative or electronic brachytherapy devices used in theatres are usually single fraction, so are outside of scope of this review.

6. Implementation

All radiotherapy providers should have local protocols for the management of unscheduled treatment interruptions and should consider how best to implement and audit their use.¹¹¹ Local protocols should be circulated to all relevant staff and displayed in planning departments and all treatment units. These protocols should be included within any departmental treatment guidance and should be incorporated into any QA standards. One RCR audit⁴⁵ has shown that different centres have adopted different strategies to deal with events causing prolongation of radical therapy. There is no evidence that one policy is better than another.⁴⁵

6.1 Availability of resources

Radiotherapy centres providing treatment with radical intent should have ready access to a minimum of two linear accelerators at any time. The RCR is aware of the difficulties that may occur during the times when machines are being replaced and it is essential that treatment standards are maintained during such periods. Centres should have their linacs matched and linked by a patient management system to allow easy transfer of patients from one machine to another when required.

On-site or hostel accommodation should be available for patients who have to travel long distances to receive their radiotherapy. It should be possible to admit patients who develop or are expected to develop medical or psychological problems during therapy. There must be appropriate transport facilities available for those attending as outpatients. Many areas have volunteer cancer services which will bring patients for therapy. Departments must ensure that they have adequate numbers of staff and arrangements should be made to ensure that radiotherapy units work normally on most if not all bank holidays.¹⁰³

Each department should ensure that at least one of their staff has the ability to understand and perform radiobiologically based calculations or arrange an alternative way to provide the service.

6.2 Patient-specific reminders at the time of prescription or treatment

These may include prompts within electronic prescribing systems and proformas within case records. Clinicians prescribing treatments should be made aware of interruptions that may be expected to arise during the planned course of therapy to allow them to agree prospective remedial action when prescribing.

6.3 Communication

Clearly, communication is necessary not just for relevant staff but also for patients. Staff in hospitals referring patients to the centre will also require appropriate information concerning the need for continuity of treatment. Patient understanding of the importance of this issue requires specific written information that should be given no later than the planning appointment.

6.4 Audit

Hospital managers, clinical directors, head radiographers and heads of radiotherapy physics departments, directors of ambulance services, clinicians and many others will want access to data associated with the implementation of these guidelines. Any computerised radiotherapy management system should incorporate software to allow a standard audit of this aspect of delivery of treatment.

6.5 Audit of key outcome indicators

The major outcome indicator following radical radiotherapy is local tumour control. Patients receiving radical radiotherapy should be the subject of regular audit. The possible effect of unscheduled prolongation of treatment on local control should form part of that continuing audit programme. As the collation of cancer outcomes data improves, the development of the National Radiotherapy Data Set (RTDS) has opportunities to audit the outcome of radical treatment from each cancer centre and collate it centrally.

Analysis of this master database would facilitate a regular review of those tumour types in Category 1.

The Australian Clinical Indicator Service Manual for Radiation Oncology (version 5)¹¹⁶ recommends establishing the planned duration of all Category 1 patients at the outset and auditing any prolongation of more than two days. In the UK a prospective registry of all Category 1 patients should be maintained and extension of planned treatment duration by two days or more should be reviewed for lessons learnt at a local clinical governance meetings.

6.6 Quality assurance

As for all QA standards, the operation of the local protocol must be monitored and modifications introduced where necessary.

6.7 Funding

Adequate funding should be included in all service delivery contracts to ensure that adequate facilities are available to guarantee continuity of treatment for patients receiving radical radiotherapy. Departmental budgets must have provision to cover overtime payments at weekends or public holidays.

6.8 Supervision

There should be a designated person in each department to monitor the frequency of interruptions arising in treatments, determine their cause and develop procedures to prevent their occurrence.

6.9 Teaching

It is essential that teaching in radiation oncology should formally address the issue of unscheduled treatment interruptions and a strong case can be made for national courses at a higher level to ensure more uniform standards.

6.10 Radiobiology support

Calculation of biological corrections should be carried out by appropriately trained physicists or clinicians: few consider themselves to be expert in these procedures in the UK.

A national resource for checking or advising on radiobiological calculations would also be helpful and could be organised as an e-network; such a service could also advise on compensation for over- and underdosage in radiotherapy.

7. Governance

7.1 Responsibilities associated with the introduction of biologically corrected doses

The correction of unscheduled interruptions in therapy results in a change in the patient's proposed therapy. Where the patient is transferred to a second machine or is treated on a weekend day, it should not be necessary to alter the consent form. It should also be remembered that the introduction of twice-daily treatment as a means to compensate may have an effect on tumour control and long-term morbidity.

7.2 Changes in treatment

The adoption of a biological correction will alter the treatment schedule and may affect outcomes in terms of cure and morbidity. In keeping with Ionising Radiation (Medical Exposure) Regulations (IR(ME)R)¹¹² guidelines, changes in the management of the patient – fractionation, dose schedule – must be authorised and justified by the practitioner, usually the consultant. All clinical decisions regarding changes in therapy should be discussed with the patient and properly documented. The patient should re-consent once the changes have been agreed with the physics staff or appropriately trained operator if the clinician feels that the outcome or side-effects may be altered considerably.

This document was approved by the Clinical Oncology Professional Support and Standards Board on: 21 September 2018.

Appendix A. The coding for evidence-based recommendations

The types of evidence and the grading of recommendations used within this document are based on those previously proposed by the Scottish Intercollegiate Guidelines Network and utilised effectively in earlier editions of these guidelines.²⁸

Recommendation		Evidence	
Grade	Source	Level	Type
A	At least one meta-analysis, systematic review of randomised, controlled trials (RCTs) or RCT rated as 1 ⁺⁺ and directly applicable to the target population; or a body of evidence consisting principally of studies rated as 1 ⁺ , directly applicable to the target population and demonstrating overall consistency of results	1 ⁺⁺	High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias.
		1 ⁺	Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias.
		1	Meta-analyses, systematic reviews of RCTs or RCTs with a high risk of bias.
B	A body of evidence including studies rated as 2 ⁺⁺ , directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated from studies rated as 1 ⁺⁺ or 1 ⁺	2 ⁺⁺	High-quality systematic reviews. High-quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.
		2 ⁺	Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal.
		2	Case control or cohort studies with a high risk of confounding or bias and a significant probability that the relationship is not causal.
C	A body of evidence including studies rated as 2 ⁺ , directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence rated as 2 ⁺⁺	3	Non-analytical studies; for example, case reports, case series.
D	Evidence level 3 or 4; or extrapolated evidence from studies rated as 2 ⁺	4	Expert opinion.

Appendix B. Worked examples of biological compensation

Recommended format for performing radiobiological compensations

The table below (adapted from Dale *et al* 2002¹⁹ with small modifications) identifies the main methods for compensation once a gap has occurred and identifies the associated benefits and difficulties.

Method	Benefit	Potential difficulty
1) Retain overall time and dose per fraction by treating on weekend days as necessary.	Overall time, fraction size, interfraction interval and therapeutic index maintained.	May not be feasible for gaps occurring near the end of a schedule.
2) Retain overall time and dose per fraction by treating twice daily as necessary.	Overall time and fraction size maintained.	Possible increase in late-normal tissue damage if many bi-daily fractions have to be used sequentially and/or if the daily interfraction intervals are all less than six hours.
3) Retain overall time by increasing dose per fraction for same number of post-gap days as there were gap days.	Overall time retained by accepting reduced number of fractions. Still utilises one fraction on each treatment day.	Not suitable for schedules which already use high dose per fraction. Therapeutic index adversely affected; that is, seeking equivalence for tumour control gives increase in late reactions. Seeking equivalence for late reactions leads to tumour underdosage.
4) Retain overall time by using smaller number of larger fractions after the gap.	Overall time retained. Still one fraction per day.	As above.
5) Accept that treatment extension is unavoidable and deliver extra fractions, using increased dose per fraction to minimise the extension duration.	Allows at least partial restoration of the prescribed schedule.	Therapeutic index adversely affected. Might require acceptance of both reduced tumour control and increased late effects.
6) As for 5 but use twice-daily fractions and a slightly longer treatment extension.	As above.	As for 5 but deterioration in therapeutic index may not be so marked.

Calculation process

It should be noted that these radiobiological calculations are based on linear-quadratic models with allowances for tumour proliferation. These are best-fit models formulated from experimental data.¹¹⁶ They are very sensitive to tumour and normal tissue α/β values, estimates for which have varied widely when such models are applied to clinical data.

Uncertainties in these inputs will be necessarily reflected in the outputs from these calculations. Nevertheless, they may be applied as a guide to the magnitude of dose correction required to compensate for prolongation in overall treatment time. It is ultimately the responsibility of the individual clinician to select the most appropriate values for the equations.

While each example of a treatment interruption is to some extent unique and will require its own solution, it is possible to adopt a standardised approach to compensation. The suggested method involves concentrating first on the normal tissue BED value in order to identify what can be done to effect compensation without exceeding tolerance. After that, the necessary compromises may be explored and evaluated.

Once an unscheduled gap has occurred, first determine the remaining treatment time and the number of fractions which, according to the prescribed schedule, are still to be delivered. Determine if there are ways of delivering these treatment fractions which would allow the originally prescribed treatment time to be maintained; for example, by treating at weekends or by giving all or part of the remaining treatment twice daily. If this is possible then a radiobiological compensation should not be necessary. (Examples 1 and 2 later in this Appendix relate to such a case.) If this option is not feasible (that is, it is not possible to complete treatment within the prescribed treatment time) then the following steps should be carried out. The relevant equations to be used are listed below.

1. First calculate the normal tissue BED for the prescribed schedule using Eq(A). This calculation should make use of the dose actually received by the critical normal tissue, if this is different from the prescribed tumour dose.
2. Determine the respective pre-gap normal-tissue BED, also using Eq(A).
3. The difference between the BEDs calculated in (1) and (2) determines the late-normal BED 'still to give' (the post-gap BED).
4. Review the various treatment options (such as twice-daily fractionation, hyperfractionation and increased fraction sizes) to ascertain which will be likely to produce the minimum extension to the treatment time, then calculate the required dose per fraction to achieve the required late-normal BED value.
5. For the selected option, calculate the associated tumour BED using Eq(B), remembering to make allowance for the extended time (Examples 3 and 4 below demonstrate different versions of this scenario).
6. Review the final tumour and normal tissue BEDs which will result from the preferred compensation option. If the tumour BED is significantly smaller than that originally prescribed, a degree of clinical judgement may be required in order to 'fine-tune' the compensation to arrive at a reasonable compromise. (Example 4 illustrates the dilemmas which become more critical in such cases.)

It is stressed that these are general steps. For example, if the favoured compensation option involves several closely spaced fractions after the gap, a modified BED formula must be used^{19,118} in order to take account of the possible enhancement to normal tissue toxicity as a consequence of incomplete repair. It is suggested that if twice-daily fractions are to be given on two/three or more successive days then the effects of incomplete repair should be considered, especially if brain or spinal tissue is at risk.

Equations

Calculation of normal tissue BED (for well-spaced fractions):

$$\text{Eq (A): } BED = Nd \times \left[1 + \frac{d}{\alpha/\beta} \right]$$

where N is the number of (well-spaced) fractions and d the dose per fraction. The recommended generic value of α/β is 3 Gy, the important exception being for spinal cord, for which a value of 2 Gy should be used.

Calculation of tumour BED:

$$\text{Eq (B): } BED = Nd \times \left[1 + \frac{d}{\alpha/\beta} \right] - K \times (T - T_{\text{delay}})$$

where T is the overall treatment time and T_{delay} is the time elapsed from the beginning of treatment before the onset of rapid repopulation. K is the daily BED-equivalent (units Gy-day⁻¹) of repopulation. The generic tumour α/β value is usually taken to be 10 Gy but there are some exceptions, important examples being breast and prostate cancer.

Further details and worked examples are given by Bentzen *et al.*¹¹⁸

Worked examples

Worked Examples 1–3 each consider ways of handling five-day gaps. In practice, the majority of unscheduled interruptions will probably involve interruptions of less than five days and are correspondingly easier to deal with. All examples involve a reference schedule of 70 Gy delivered in 35 fractions over 46 days, typically used for Category 1 head and neck tumours. The overall time of 46 days corresponds to a treatment beginning on a Monday, continues with daily fractionation for seven weeks with no treatment at weekends and finishes on a Friday. For a similar 35-fraction schedule which begins mid-week, the treatment time will be longer (because the treatment will extend into an eighth week) and specific calculations should allow for this.

For other schedules, such as the commonly used four-week treatments, the principle involved in determining a method of compensation is exactly the same as set out in the seven-week examples used here. In such cases, however, there is more concern about twice-daily treatments if the dose per fraction is already significantly larger than 2 Gy, because of the greater potential for incomplete repair.

Example 1. Loss of all of the third week (five fractions) of a treatment schedule of 70 Gy/35 fractions/46 days

Assuming the treatment began on a Monday, the intended overall treatment time is 46 days. After the gap, treatment resumes on the Monday of the fourth week of the schedule. Ten fractions have been delivered; 25 remain to be given. If treatment is to be completed on the prescribed finishing date the available number of days (including weekends) is 26. Thus, the missed dose in the gap can be compensated for by delivering the remainder of the treatment on weekdays (20 fractions) and on five of the six remaining weekend days.

This does not involve changing the fraction size and, as the treatment is not extended, constitutes a 'good' compensation.

If weekend treatments are not feasible a good compensation is still possible if, on five of the 20 remaining treatment days, two fractions are delivered instead of one. The important proviso is that the twice-daily fractions must be delivered with a minimum time gap between them of six hours. It is further recommended that the days on which twice-daily treatments are delivered are not consecutive but spaced throughout the available time period. In this instance, Fridays are a good choice for delivery of some of the twice-daily fractions as there is a greater opportunity for completion of repair before treatment resumes the following week. In cases where the individual fraction sizes are appreciably greater than 2 Gy, particular care needs to be taken with the use of bi-daily fractionation since the issue of interfraction spacing and the distribution of the bi-daily treatment days throughout the remaining schedule becomes more critical.

Example 2. Loss of all of the sixth week (five fractions) of a treatment schedule of 70 Gy/35 fractions/46 days

After the gap, treatment resumes on the Monday of the seventh week of the schedule. Twenty-five fractions have been delivered and ten remain to be given. Ideally these ten fractions should be delivered over the five remaining treatment days so as not to extend the treatment. The missed dose can therefore be compensated for by delivering the remainder of the treatment as twice-daily fractions (minimum of six hours apart) in each weekday of the final week. This does not involve changing the fraction size and, as the treatment is not extended, constitutes a good compensation. A better solution, if feasible, would be also to make use of the weekend before the final week of treatment, thus providing seven days within which ten fractions have to be delivered. Bi-daily fractionation could be used, for example, on Monday, Wednesday and Friday, single fractions on the other four days. The advantage of the latter scheme is that it reduces the likelihood of creating excess normal tissue damage in the event that there is incomplete repair between fractions.

Examples 1 and 2 do not involve changing fraction size or overall time and, provided there is reasonable spacing between treatment days on which bi-daily treatment is given, do not invoke any quantitative evaluations or serious radiobiological dilemmas. The following examples illustrate the compromises involved in more difficult cases.

Example 3. Loss of all of the seventh week (five fractions) of a treatment schedule of 70 Gy/35 fractions/46 days

In this example, the unscheduled gap extends to the time when treatment should have finished and any form of compensation will therefore extend the treatment time beyond the scheduled time. It is, therefore, necessary to use calculations to first determine how much normal tissue BED there is 'still to give' after the gap.

For the prescribed treatment the normal tissue BED (BED_3) is, from Eq(A):

$$35 \times 2 \times \left[1 + \frac{2}{3} \right] = 116.7 \text{ Gy}_3$$

The BED_3 delivered before the gap is:

$$30 \times 2 \times \left[1 + \frac{2}{3}\right] = 100 \text{ Gy}_3$$

The allowable BED_3 left to give without increasing tolerance is therefore $116.7 - 100 = 16.7 \text{ Gy}_3$.

The tumour BED (BED_{10}) for the prescribed schedule is, using Eq(B) with $K = 0.9$ and $T_{\text{delay}} = 28$ days:

$$35 \times 2 \times \left[1 + \frac{2}{10}\right] - (46 - 28) \times 0.9 = 67.8 \text{ Gy}_{10}$$

We begin by assuming that the missing dose is replaced by treating with five 2 Gy fractions over a full extra (eighth) week, beginning on a Monday. On completion, the overall time is seven days longer than scheduled. With a daily BED-equivalent of tumour repopulation of $0.9 \text{ Gy}\cdot\text{day}^{-1}$, the tumour BED_{10} will be lower than intended by an amount $7 \times 0.9 = 6.3 \text{ Gy}_{10}$, that is, it will be reduced to $67.8 - 6.3 = 61.5 \text{ Gy}_{10}$, a fall of over 9%. The late normal BED_3 will be as originally prescribed.

If instead, the outstanding daily treatments are given in the period Saturday–Wednesday, the net treatment extension is five days; that is, the tumour BED_{10} is reduced by $5 \times 0.9 = 4.5 \text{ Gy}_{10}$ (6.6%). A further alternative is to treat two fractions per day on Saturday and Monday with one fraction on Sunday, thus extending treatment by only three days. In this case, the tumour BED_{10} will be lowered by an even smaller amount of $3 \times 0.9 = 2.7 \text{ Gy}_{10}$ (4%). In each of these instances, the normal tissue BED_3 will again be as prescribed.

The dilemmas arise when attempts are made to increase the total dose to restore the tumour BED_{10} to that originally intended; in this case it is impossible to do so without increasing the normal tissue BED_3 beyond that originally prescribed. Delivering extra doses by treating with extra fractions has the effect of further extending the treatment time, which may compound the original problem. Increasing the dose per fraction helps offset the deleterious influence of the treatment extension but, because of the greater sensitivity of the late-responding critical tissue to changes in dose per fraction, will increase the normal tissue BED proportionately more than that for the tumour.

We next consider an instance where it is felt essential to restore the tumour BED_{10} to what it should be, initially without regard for the effect on the normal tissue. We assume the option of treating additionally over the weekend is to be adopted, taking the overall time to $46 + 5 = 51$ days.

The tumour BED_{10} of 67.8 Gy_{10} is to be maintained. Therefore, for the whole schedule (pre-gap plus post-gap):

BED_{10} (pre-gap) + BED_{10} (post-gap) – tumour repopulation factor = prescribed BED_{10}

$$30 \times 2 \times \left[1 + \frac{2}{10}\right] + 5 \times d \times \left[1 + \frac{d}{10}\right] - (51 - 28) \times 0.9 = 67.8 \text{ Gy}_{10}$$

where d is the new value of dose per fraction to be utilised over the five fractions. The solution for d in the above equation is $d = 2.62$ Gy; that is, 5×2.62 Gy will restore the tumour BED_{10} to that initially prescribed. Again, it should be noted that the required extra BED_{10} of $(5 \times 0.9 =) 4.5$ Gy_{10} cannot be added simply pro rata across the five 2 Gy fractions. The values of the biological Gy_{10} and the physical Gy units are different and they cannot be added; to do so would lead to an even higher fraction dose of 2.9 Gy.

For the normal tissue, the compensated treatment increases the BED_3 to:

BED_3 (pre-gap) + BED_3 (post-gap), that is:

$$100 + 5 \times 2.62 \times \left[1 + \frac{2.62}{3} \right] = 124.5 \text{ Gy}_3$$

Thus, the revised treatment delivers a 6.7% excess in normal tissue BED_3 . To evaluate what this compensated scheme would mean in terms of the equivalent dose in a schedule delivered with 2 Gy fractions we note that, by re-arrangement of Eq(A):

$$\text{Total dose in 2 Gy fractions} \times \left[1 + \frac{2}{3} \right] = 124.5$$

The total dose in 2 Gy fractions would be 74.7 Gy. Thus, the given normal tissue BED_3 is approximately equivalent to just over 37×2 Gy fractions.

If this is considered to be excessive it is possible to 'split the difference', that is, aim to achieve a tumour BED_{10} which is a little less than that prescribed while accepting a small increase in normal tissue BED_3 . Such a result may be arrived at by trial and error processing of different values of dose per fraction. For instance, in the above example an intermediate dose per fraction of 2.3 Gy would deliver a total tumour BED_{10} of:

BED_{10} (pre-gap) + BED_{10} (post-gap) – tumour repopulation factor:

$$\begin{aligned} 30 \times 2 \times \left[1 + \frac{2}{10} \right] + 5 \times 2.3 \times \left[1 + \frac{2.3}{10} \right] - (51 - 28) \times 0.9 \\ = 65.4 \text{ Gy}_{10} \end{aligned}$$

The normal tissue BED is:

BED_3 (pre-gap) + BED_3 (post-gap):

$$30 \times 2 \times \left[1 + \frac{2}{3} \right] + 5 \times 2.3 \times \left[1 + \frac{2.3}{3} \right] = 120.3 \text{ Gy}_3$$

Thus, with 2.3 Gy fractions in the compensation, the tumour and normal tissue BEDs are respectively 3.5% lower and 3.1% higher than for the uninterrupted schedule. The effects of alternative values of dose per fraction could be tested, as appropriate, using the same process. It is stressed that the process of hypofractionating treatment after the gap is not necessarily the best option: a better result is likely to be obtained if some extra fractions can be used (via bi-daily fractionation) in order to restrict use of excessive fraction size.

Worked example for a more complex case

Unscheduled interruptions of longer than five days are generally more difficult to deal with as there is less chance of completing treatment without incurring a significant extension of the treatment time. The following example highlights such cases.

Example 4. Loss of all of the sixth and seventh weeks (ten fractions) of a treatment schedule of 70 Gy/35 fractions/46 days

As in Example 3, the unscheduled gap runs right up to the time when treatment should have finished. In this case however, a very significant part of the treatment has yet to be delivered. In order to minimise the consequent extension to treatment time it is inevitable that an increased dose per fraction will need to be considered if treatment is to be delivered in once-daily fractions.

We initially attempt to complete treatment in five fractions delivered during the eighth week – the treatment time is extended by seven days to 53 days. We first aim to match the prescribed late-normal tissue BED_3 (116.7 Gy₃), that is, the dose per fraction to use is d , where d is solved from:

$$BED_3(\text{pre-gap}) + BED_3(\text{post-gap}) = \text{Required } BED_3 \text{ that is:}$$

$$\text{for which } d = 3.22 \text{ Gy}$$

This same dose per fraction would produce a resultant tumour BED_{10} of:

$$BED_{10}(\text{pre-gap}) + BED_{10}(\text{post-gap}) - \text{tumour repopulation factor:}$$

$$25 \times 2 \left[1 + \frac{2}{10} \right] + 5 \times 3.22 \times \left[1 + \frac{3.22}{10} \right] - (53 - 28) \times 0.9 = 58.8 \text{ Gy}_{10}$$

Thus, despite using a large dose per fraction for the last five fractions, the resultant tumour BED_{10} is still 13.2% less than prescribed. If the weekend prior to the eighth treatment week is used for treatment, then seven fractions may be delivered, leading to a fractional dose of 2.57 Gy and a tumour BED_{10} of 60.1 Gy₁₀. If 11 fractions are distributed over the seven available treatment days (by treating bi-daily on four of them) the required fractional dose drops to 1.87 Gy, the tumour BED_{10} then being 61.9 Gy₁₀. This latter value is still 8.7% short of the prescribed tumour BED_{10} (67.8 Gy₁₀), thus some degree of compromise, achieved by increasing dose per fraction as illustrated in the previous example, might be considered. In extreme cases, three times-daily fractionation could be considered, but only after careful consideration of the potential for detriment from incomplete repair.

If weekend or twice-daily fractionation cannot be accommodated, then it might be considered necessary to carry out the remaining treatment over two full working weeks – extending treatment into an eighth and ninth week – making the overall treatment time 46 + 14 = 60 days. For this, the dose per fraction (d) ideally required to maintain the tumour BED_{10} is obtained from:

$$BED_{10}(\text{pre-gap}) + BED_{10}(\text{post-gap}) - \text{tumour repopulation factor:}$$

$$25 \times 2 \times \left[1 + \frac{2}{10} \right] + 10 \times d \times \left[1 + \frac{d}{10} \right] - (60 - 28) \times 0.9 = 67.8 \text{ Gy}_{10}$$

for which $d = 2.85$ Gy, leading to an associated BED_3 of 138.9 Gy₃, which is 19% higher than prescribed. This result demonstrates the alternative dilemma associated with further extending the treatment to avoid weekend and twice-daily treatments: the total dose to be delivered is again increased by the extension into the ninth week, with a consequent penalty to BED_3 .

Some further clinical considerations

1. Concurrent chemotherapy schedules will have an associated BED but they will be the same for treatments regardless of gaps. Consequently, no allowance is necessary. However, it would seem prudent not to deliver concomitant chemotherapy on the same day as accelerated compensatory treatments.
2. Maintaining a tumour BED may be considered necessary in some indications, where no salvage therapy is possible. The patient may also have strong views on whether to preserve tumour control and accept higher risks of more serious normal tissue side-effects and the possibility of their subsequent management using surgery and so on. In cases where the risk of a severe normal tissue reaction is high and not amenable to surgical or other correction (such as spinal myelitis) then a more conservative approach would be favoured.
3. Where feasible, field size reductions can be used in the later stages of compensation therapy to minimise the normal tissue volume exposed to a higher BED where relevant.
4. A change in the sequence of treatment might be allowed to save a further loss of time: for example, earlier introduction of a Phase 2 boost technique is possible in some instances (medulloblastoma, breast,) depending on the circumstances. If external beam treatment is poorly tolerated, use of a slightly higher dose of a more focal form of radiotherapy such as brachytherapy might be indicated.
5. In cases where it is technically not possible to perform a treatment such as brachytherapy following a course of external beam treatment, the use of chemotherapy in the enforced gap should be considered.

References

1. The Royal College of Radiologists. *Guidelines for the management of the unscheduled interruption or prolongation of a radical course of radiotherapy*. London: The Royal College of Radiologists, 1996.
 2. The Royal College of Radiologists. *Guidelines for the management of the unscheduled interruption or prolongation of a radical course of radiotherapy*, second edition. London: The Royal College of Radiologists, 2002.
 3. The Royal College of Radiologists. *The timely delivery of radical radiotherapy: standards and guidelines for the management of unscheduled treatment interruptions*, third edition. London: The Royal College of Radiologists, 2008.
 4. Hendry JH, Bentzen SM, Dale RG *et al*. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. *Clin Oncol (R Coll Radiol)* 1996; **8**(5): 297–307.
 5. Milecki P, Kruk-Zagajewska A, Szmaja Z and Cerkaska-Głuszak B. The influence of the duration of a break in the course of postoperative radiotherapy on the results of treatment of patients with total laryngectomy due to cancer. *Otolaryngol Pol* 1997; **51**(1): 37–46.
 6. Hoffstetter S, Marchal C, Peiffert D *et al*. Treatment duration as a prognostic factor for local control and survival in epidermoid carcinomas of the tonsillar region treated by combined external beam irradiation and brachytherapy. *Radiother Oncol* 1997; **45**(2): 141–148.
 7. Chatani M, Matayoshi Y, Masaki N and Inoue T. High-dose rate intracavitary irradiation for carcinoma of the uterine cervix. The adverse effect of treatment prolongation. *Strahlenther Onkol* 1997; **173**(7): 379–384.
 8. Perez CA, Grigsby PW, Castro-Vita H and Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. *Int J Radiat Oncol Biol Phys* 1995; **32**(5): 1,275–1,288.
 9. Jones B and Dale RG. The reduction of tumour control with increasing overall time: mathematical considerations. *Br J Radiol* 1996; **69**(825): 830–838.
 10. Barton MB, Keane TJ, Gadalla T and Maki E. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. *Radiother Oncol* 1992; **23**(3): 137 – 143.
 11. Duncan W, MacDougall RH, Kerr GR and Downing D. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer. *Radiother Oncol* 1996; **41**(3): 203–207.
 12. Sackett DL. *Clinical epidemiology: A Basic Science for Clinical Medicine*, second edition. Philadelphia: Lippincott Williams and Wilkins, 1991.
 13. Chen Z, King W, Pearcey R, Kerba M and Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. *Radiother Oncol* 2008; **87**(1): 13–16.
 14. Robertson C, Robertson AG, Hendry JH *et al*. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. *Int J Radiat Oncol Biol Phys* 1998; **40**(2): 319–329.
 15. Hendry JH, Roberts SA Slevin NH *et al*. Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centres in Manchester, UK and Toronto, Canada. *Radiother Oncol* 1994; **31**(1): 14–22.
 16. Bese NS, Sut PA and Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. *Oncology* 2005; **69**(3): 214–223.
 17. Bese NS, Sut PA, Sut N and Ober A. The impact of treatment interruptions on locoregional control during postoperative breast irradiation. *J BUON* 2007; **12**(3): 353–359.
 18. Thames HD, Peters LJ and Ang KK. Time-dose considerations for normal-tissue tolerance. *Front Radiat Ther Oncol* 1989; **23**: 113–130.
-

19. Dale RG, Hendry JH, Jones B *et al*. Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules. *Clin Oncol (R Coll Radiol)* 2002; **14**(5): 382–393.
20. www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/radiotherapy/about (last accessed 20/11/2018)
21. Munro TR and Gilbert CW. The relation between tumour lethal doses and the radiosensitivity of tumour cells. *Br J Radiol* 1961; **34**: 246–251.
22. International Commission on Radiation Units and Measurements. *ICRU Report 62. Prescribing, recording and reporting photon beam therapy: Supplementary to ICRU Report 50*. Bethesda MD: International Commission on Radiation Units and Measurements, 1999.
23. Ellis F. *Time and dose relationships in radiation biology as applied to radiotherapy*. At the conference on Time and Dose Relationships in Radiation Biology as Applied to Radiotherapy: Held at Carmel, California, September 1969. Brookhaven National Laboratory BNL, 1969.
24. Cell Proliferation and Growth Rate of Tumours. In Steel GG and Begg AC (Eds) *Basic clinical radiobiology*. Oxford: Oxford University Press, 2002.
25. Haustermans KM, Hofland I, Van Poppel H *et al*. Cell kinetic measurements in prostate cancer. *Int J Radiat Oncol Biol Phys* 1997; **37**(5): 1067–1070.
26. Rew DA and Wilson GD. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. *Eur J Surg Oncol* 2000; **26**(4): 405–417.
27. Bese NS, Hendry J and Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. *Int J Radiat Oncol Biol Phys* 2007; **68**(3): 654–661.
28. Pallari E, Fox AW and Lewison G. Differential research impact in cancer practice guidelines' evidence base: lessons from ESMO, NICE and SIGN. *ESMO Open* 2018; **3**(1): e000258.
29. Kwong DL, Sham JS, Chua DT *et al*. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 1997; **39**(3): 703–710.
30. Lindstrom MJ and Fowler JF. Re-analysis of the time factor in local control by radiotherapy of T3T4 squamous cell carcinoma of the larynx. *Int J Radiat Oncol Biol Phys* 1991; **21**(3): 813–817.
31. Skladowski K, Law MG, Maciejewski B and Steel GG. Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. *Radiother Oncol* 1994; **30**(2): 109–120.
32. Guyatt GH, Oxman AD, Kunz R *et al*. Going from evidence to recommendations. *BMJ* 2008; **336**: 1,049–1,051.
33. Read G. Radiotherapy: effective treatment at low cost! *Clin Oncol (R Coll Radiol)* 1995; **7**(5): 275–276.
34. Barton MB, GebSKI V, Manderson C and Langlands AO. Radiation therapy: are we getting value for money? *Clin Oncol (R Coll Radiol)* 1995; **7**(5): 287–292.
35. Glazebrook GA. Radiation therapy: a long term cost benefit analysis in a North American region. *Clin Oncol (R Coll Radiol)* 1992; **4**(5): 302–305.
36. Ploquin NP and Dunscombe PB. The cost of radiation therapy. *Radiother Oncol* 2008; **86**(2): 217–223.
37. Scottish Oncology and Radiology Audit Group. *An audit of the importance of fractionation regimen and treatment gaps in the treatment of carcinoma of the larynx. report to CRAG on behalf of the Scottish Oncology and Radiology Audit Group CA94/14*. Scotland: Scottish Oncology and Radiology Audit Group, 1997.
38. Overgaard J, Hjelm-Hansen M, Johansen LV and Andersen AP. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. *Acta Oncol* 1988; **27**(2): 147–152.
39. Hopewell JW, Nyman J and Turesson I. Time factor for acute tissue reactions following fractionated irradiation: a balance between repopulation and enhanced radiosensitivity. *Int J Radiat Biol* 2003; **79**(7): 513–524.
40. Harari PM and Fowler JF. Idealized versus realized overall treatment times. *Int J Radiat Oncol Biol Phys* (1994); **29**(1): 209–211.

41. Lindberg RD, Jones K, Garner HH *et al.* Evaluation of unplanned interruptions in radiotherapy treatment schedules. *Int J Radiat Oncol Biol Phys* 1988; **14**(4): 811–815.
42. Bentzen SM. Time-does relationships for human tumors: estimation from nonrandomized studies. In *Current topics in clinical radiobiology of tumors*. Hans-Peter, Beck-Bornholdt (Eds). Berlin Heidelberg: Springer, 1993.
43. Bentzen SM, Johansen LV, Overgaard J and Thames HD. Clinical radiobiology of squamous cell carcinoma of the oropharynx. *Int J Radiat Oncol Biol Phys* 1991; **20**(6): 1,197–1,206.
44. Bujko K, Skoczylas JZ, Bentzen SM *et al.* A feasibility study of concomitant boost radiotherapy for patients with cancer of the supraglottic larynx. *Acta Oncol* 1993; **32**(6): 637–640.
45. James ND, Robertson G, Squire CJ *et al.* A national audit of radiotherapy in head and neck cancer. *Clin Oncol (R Coll Radiol)* 2003; **15**(2): 41–46.
46. James ND, Williams MV, Summers ET *et al.* The management of interruptions to radiotherapy in head and neck cancer: an audit of the effectiveness of national guidelines. *Clin Oncol (R Coll Radiol)* 2008; **20**(8): 599–605.
47. Suwinski R, Sowa A, Rutkowski T *et al.* Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. *Int J Radiat Oncol Biol Phys* 2003; **56**(2): 399–412.
48. Delaloye JF, Coucke PA, Pampallona S and De Grandi P. Effect of total treatment of time on event-free survival in carcinoma of the cervix. *Gynecol Oncol* 1996; **60**(1): 42–48.
49. Stuschke M and Pöttgen C. Localized small-cell lung cancer: which type of thoracic radiotherapy and which time schedule. *Lung Cancer* 2004; **45**(Suppl 2): S133–S137.
50. Machtay M, Hsu C, Komaki R *et al.* Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. *Int J Radiat Oncol Biol Phys* 2005; **63**(3): 667–671.
51. Slevin NJ, Hendry JH, Roberts SA and Agren-Cronqvist A. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. *Radiother Oncol* 1992; **24**(4): 215–220.
52. Van den Bogaert W, Van der Leest A, Rijnders A *et al.* Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? *Radiother Oncol* 1995; **36**(3): 177–182.
53. Coles CE, Burgess L and Tan LT. An audit of delays before and during radical radiotherapy for cervical cancer – effect on tumour cure probability. *Clin Oncol (R Coll Radiol)* 2003; **15**(2): 47–54.
54. Chen SW, Liang J A, Yang SN, Ko HL and Lin FJ. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. *Radiother Oncol* 2003; **67**(1): 69–76.
55. Hama Y, Uematsu M, Nagata I *et al.* Carcinoma of the uterine cervix: twice- versus once-weekly high-dose-rate brachytherapy. *Radiology* 2001; **219**(1): 207–212.
56. Girinsky T, Rey A, Roche B *et al.* Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. *Int J Radiat Oncol Biol Phys* 1993; **27**(5): 1,051–1,056.
57. Fyles A, Keane TJ, Barton M and Simm J. The effect of treatment duration in the local control of cervix cancer. *Radiother Oncol* 1992; **25**(4): 273–279.
58. Cox JD, Pajak TF, Asbell S *et al.* Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. *Int J Radiat Oncol Biol Phys* 1993; **27**(3): 493–498.
59. Chen M, Jiang GL, Fu XL *et al.* The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer. *Lung Cancer* 2000; **28**(1): 11–19.
60. Fowler JF and Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. *Int J Radiat Oncol Biol Phys* 2000; **46**(2): 516–517.
61. McMillan MT, Ojerholm E, Verma V *et al.* Radiation treatment time and overall survival in locally advanced non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2017; **98**(5): 1,142–1,152.

62. Videtic GM, Fung K, Tomiak AT *et al.* Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. *Lung Cancer* 2001; **33**(2–3): 249–258.
63. Turrisi AT 3rd, Kim K, Blum R *et al.* Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999; **340**(4): 265–271.
64. Faivre-Finn C, Snee M, Ashcroft L *et al.* Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol* 2017; **18**(8): 1,116–1,125.
65. Kal HB, El Sharouni SY and Wijrdeman HK. Radiotherapy for oesophageal cancer. *Ann Oncol* 1999; **10**(3): 359–360.
66. Sykes AJ, Burt PA, Slevin NJ, Stout R and Marrs JE. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. *Radiother Oncol* 1998; **48**(1): 15–21.
67. Nishimura Y, Ono K, Tsutsui K *et al.* Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. *Int J Radiat Oncol Biol Phys* 1994; **30**(5): 1,099–1,105.
68. Powell ME, Hoskin PJ, Saunders MI, Foy CJ and Dische S. Continuous hyperfractionated accelerated radiotherapy (CHART) in localized cancer of the esophagus. *Int J Radiat Oncol Biol Phys* 1997; **38**(1): 133–136.
69. del Charco JO, Bolek TW, McCollough WM *et al.* Medulloblastoma: time–dose relationship based on a 30-year review. *Int J Radiat Oncol Biol Phys* 1998; **42**(1): 147–154.
70. Santos MA, Viégas CM *et al.* Timing of radiation in children with medulloblastoma/PNET. *Pediatr Blood Cancer* 2007; **48**(4): 416–422.
71. Taylor RE, Bailey CC, Robinson K *et al.* Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. *J Clin Oncol* 2003; **21**(8): 1,581–1,591.
72. Ben-Josef E, Moughan J, Ajani JA *et al.* Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. *J Clin Oncol* 2010; **28**(34): 5,061–5,066.
73. Glynne-Jones R, Sebag-Montefiore D, Adams R *et al.* “Mind the gap” – the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). *Int J Radiat Oncol Biol Phys* 2011; **81**(5): 1,488–1,494.
74. Glynne-Jones R, Meadows HM, Lopes A, Adams RA and Sebag-Montefiore D. Compliance to chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/ CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA) according to radiotherapy (RT) dose, overall treatment time (OTT) and chemotherapy (CT) and their impact on long-term outcome: Results of ACT II. *J Clin Oncol* 2015; **33**(Suppl 15): 3,518–3,518.
75. Irwin C, Hunn M, Purdie G and Hamilton D. Delay in radiotherapy shortens survival in patients with high grade glioma. *J Neurooncol* 2007; **85**(3): 339–343.
76. Burnet NG, Jena R, Jefferies SJ, Stenning SP and Kirkby NF. Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. *Clin Oncol (R Coll Radiol)* 2006; **18**(2): 93–103.
77. Moonen L, vd Voet H, de Nijs R *et al.* Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. *Int J Radiat Oncol Biol Phys* 1998; **42**(3): 525–530.
78. Maciejewski B and Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. *Radiother Oncol* 1991; **21**(3): 163–170.
79. Näslund I, Nilsson B and Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. *Acta Oncol* 1994; **33**(4): 397–402.

80. De Neve W, Lybeert ML, Goor C, Crommelin MA and Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. *Radiother Oncol* 1995; **36**(3): 183–188.
81. Weber DC, Kurtz JM and Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. *Int J Radiat Oncol Biol Phys* 2001; **50**(3): 675–680.
82. John M, Pajak T, Flam M *et al*. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. *Cancer J Sci Am* 1996; **2**(4): 205–211.
83. Konski A, Garcia M Jr, John M *et al*. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. *Int J Radiat Oncol Biol Phys* 2008; **72**(1): 114–118.
84. Perez CA, Michalski J, Mansur D and Lockett MA. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate. *Cancer J* 2004; **10**(6): 349–356.
85. Amdur RJ, Parsons JT, Fitzgerald LT and Million RR. The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. *Int J Radiat Oncol Biol Phys* 1990; **19**(6): 1,377–1,382.
86. Brenner DJ and Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. *Int J Radiat Oncol Biol Phys* 1999; **43**(5): 1,095–1,101.
87. Lai PP, Pilepich MV, Krall JM *et al*. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. *Int J Radiat Oncol Biol Phys* 1991; **21**(4): 925–933.
88. Jones B, Hopewell JW and Dale RG. Radiobiological compensation for unintended treatment interruptions during palliative radiotherapy. *Br J Radiol* 2007; **80**(960): 1,006–1,010.
89. Fowler JF and Lindstrom MJ. Loss of local control with prolongation in radiotherapy. *Int J Radiat Oncol Biol Phys* 1992; **23**(2): 457–467.
90. The Royal College of Radiologists. *Radiotherapy dose-fractionation, second edition*. London: The Royal College of Radiologists, 2016.
91. Haviland JS, Bentzen SM, Bliss JM, Yarnold JR and START Trial Management Group. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. *Radiother Oncol* 2016; **121**(3): 420–423.
92. Robertson AG, Robertson C, Perone C *et al*. Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis. *Radiother Oncol* 1998; **48**(2): 165–173.
93. Herrmann T, Jakubek A and Trott KR. The importance of the timing of a gap in radiotherapy of squamous cell carcinomas of the head and neck. *Strahlenther Onkol* 1994; **170**(9): 545–549.
94. Roberts SA, Hendry JH, Brewster AE and Slevin NJ. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor. *Br J Radiol* 1994; **67**(800): 790–794.
95. Fu KK, Pajak TF, Trotti A *et al*. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. *Int J Radiat Oncol Biol Phys* 2000; **48**(1): 7–16.
96. Withers HR. Biological aspects of conformal therapy. *Acta Oncol* 2000; **39**(5): 569–577.
97. Fowler JF and Harari PM. Confirmation of improved local-regional control with altered fractionation in head and neck cancer. *Int J Radiat Oncol Biol Phys* 2000; **48**(1): 3–6.
98. Tarnawski R, Fowler J, Skladowski K *et al*. How fast is repopulation of tumor cells during the treatment gap? *Int J Radiat Oncol Biol Phys* 2002; **54**(1): 229–236.
99. Dale RG, Jones B, Sinclair JA, Comins C and Antoniou E. Results of a UK survey on methods for compensating for unscheduled treatment interruptions and errors in treatment delivery. *Br J Radiol* 2007; **80**(953): 367–370.

100. Koukourakis M, Hlouverakis G, Ksoma L *et al*. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. *Int J Radiat Oncol Biol Phys* 1996; **34**(2): 315–322.
101. Chen YP, Tsang NM, Tseng CK and Lin SY. Causes of interruption of radiotherapy in nasopharyngeal carcinoma patients in Taiwan. *Jpn J Clin Oncol* 2000; **30**(5): 230–234.
102. Royal College of Physicians and Joint Collegiate Council for Oncology. *Improving quality in cancer care: provision of psychological support services for cancer patients and their families*. London: Royal College of Physicians and The Royal College of Radiologists, 1996.
103. National Radiotherapy Advisory Group. *Radiotherapy: developing a world class service for England*. London: National Radiotherapy Advisory Group, 2007.
104. Saunders M, Dische S, Barrett A *et al*. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. *Radiother Oncol* 1999; **52**(2): 137–148.
105. Withers HR, Taylor JMG and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. *Acta Oncol* 1988; **27**(2): 131–146.
106. Taylor JM, Withers HR and Mendenhall WM. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. *Radiother Oncol* 1990; **17**(2): 95–102.
107. Budihna M, Skrk J, Smid L and Furlan L. Tumor cell repopulation in the rest interval of split-course radiation treatment. *Strahlentherapie* 1980; **156**(6): 402–408.
108. Maciejewski B, Preuss-Bayer G and Trott KR. The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. *Int J Radiat Oncol Biol Phys* 1983; **9**(3): 321–328.
109. Rezvani M, Fowler JF, Hopewell JW and Alcock CJ. Sensitivity of human squamous cell carcinoma of the larynx to fractionated radiotherapy. *Br J Radiol* 1993; **66**(783): 245–255.
110. Roberts SA and Hendry JH. A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity. *Int J Radiat Oncol Biol Phys* 1998; **41**(3): 689–699.
111. Grimshaw JM and Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. *Lancet* 1993; **342**(8883): 1,317–1,322.
112. UK Government. *Statutory Instrument 2017 No. 1322: The Ionising Radiation (Medical Exposure) Regulations 2017. Health and Safety Legislation*. London: Her Majesty's Stationery Office, 2017.
113. Alite F, Stang K, Balasubramanian N *et al*. Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy. *Radiother Oncol* 2016; **121**(1): 9–14.
114. Jain S, Poon I, Soliman H *et al*. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life. *Radiother Oncol* 2013; **108**(2): 320–325.
115. Jones B. Compensating for elapsed time: unintended treatment interruptions and re-treatments. In *Practical radiobiology for proton therapy planning Vol. 1*. Jones B. Bristol: IOP Science, 2017.
116. Royal Australian and New Zealand College of Radiologists. *Radiation oncology: clinical indicator user manual, version 5*. Sydney: Royal Australian and New Zealand College of Radiologists, 2017.
117. van Leeuwen CM, Oei AL, Crezee J *et al*. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. *Radiat Oncol* 2018; **13**(1): 96.
118. Bentzen SM. The linear quadratic approach in clinical practice. In *Basic clinical radiobiology*. Joiner MC (Ed). Boca Raton: Taylor & Francis Group, 2009.

Working party membership

Core working group members:

Professor Geoff Higgins, Consultant Clinical Oncologist (Co-chair), Oxford University Hospitals and Oxford Institute for Radiation Oncology

Dr Ketan Shah, Consultant Clinical Oncologist (Co-chair), Oxford University Hospitals

Ms Paula Horne, Radiotherapy Service Manager, Royal Berkshire NHS Foundation Trust

Mr Mark Gilham, Radiographer Service Manager, Norwich and Norfolk NHS Foundation Trust

Dr David Bloomfield, Medical Director Professional Practice Clinical Oncology, RCR

We are grateful for those who also contributed to the review:

Dr Vivian Cosgrove, Chair of Radiotherapy Professional Standards, Institute of Physics and Engineering in Medicine (IPEM)

Dr James Coates, Department of Oncology, University of Oxford

Professor Roger Dale, Professor of Cancer Radiobiology, Imperial College London

Professor David Dearnaley, Consultant Clinical Oncologist, The Royal Marsden

Dr David Eaton, Chair of Radiotherapy Special Interest Group, Institute of Physics and Engineering in Medicine (IPEM)

Dr Kevin Franks, Consultant Clinical Oncologist, Leeds Cancer Centre

Dr Ian Geh, Consultant Clinical Oncologist, Queen Elizabeth Hospital, Birmingham

Dr Duncan Gilbert, Consultant Clinical Oncologist, Brighton and Sussex Cancer Centre

Dr Anna Kirby, Consultant Clinical Oncologist, The Royal Marsden

Dr Phil Munro, Executive Officer Faculty of Radiation Oncology, The Royal Australian and New Zealand College of Radiologists

Dr Melanie Powell, Consultant Clinical Oncologist, The Barts London

Dr Dan Saunders, Consultant Clinical Oncologist, The Christie

Dr Ed Smith, Consultant Clinical Oncologist and Clinical Director Proton Therapy, The Christie

The Royal College of Radiologists
63 Lincoln's Inn Fields
London WC2A 3JW

+44 (0)20 7405 1282
enquiries@rcr.ac.uk
www.rcr.ac.uk
@RCRadiologists

The Royal College of Radiologists is
a Charity registered with the Charity
Commission No: 211540

The Royal College of Radiologists. *The timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions, fourth edition.* London: The Royal College of Radiologists, 2019.

Ref No. BFCO(19)1

© The Royal College of Radiologists, January 2019.

For permission to reproduce any of the content contained herein, please email: permissions@rcr.ac.uk

This material has been produced by The Royal College of Radiologists (RCR) for use internally within the specialties of clinical oncology and clinical radiology in the United Kingdom. It is provided for use by appropriately qualified professionals, and the making of any decision regarding the applicability and suitability of the material in any particular circumstance is subject to the user's professional judgement.

While every reasonable care has been taken to ensure the accuracy of the material, RCR cannot accept any responsibility for any action taken, or not taken, on the basis of it. As publisher, RCR shall not be liable to any person for any loss or damage, which may arise from the use of any of the material. The RCR does not exclude or limit liability for death or personal injury to the extent only that the same arises as a result of the negligence of RCR, its employees, Officers, members and Fellows, or any other person contributing to the formulation of the material.